Literature DB >> 29313289

Incidence, Survival, and Predictors of Lymph Node Involvement in Early-Stage Gastric Signet Ring Cell Carcinoma in the US.

Sridevi K Pokala1, Chao Zhang2,3, Zhengjia Chen2,3, Anthony M Gamboa4, Sarah L Cristofaro5, Steven A Keilin5, Qiang Cai5, Field F Willingham6.   

Abstract

INTRODUCTION: The incidence, survival, and propensity for nodal metastasis in early-stage gastric signet ring cell carcinoma have not been defined in the United States. These data are critical determinants for treatment allocation.
METHODS: Cases of gastric signet ring cell carcinoma were extracted from the national SEER database for the years 2004-2013. Age-standardized incidence was derived. Survival was calculated using the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify predictors of nodal metastasis. Exclusion criteria included neoadjuvant radiotherapy and lack of histologic or nodal data.
RESULTS: A total of 10,624 cases were initially identified. The analysis cohort included 506 cases with early T-stage N0M0 disease following exclusions. The incidence was 0.094 per 100,000 person-years. The 5-year survival rate was 82.8%. Tumor stage (p < 0.001) and size (p < 0.001) were independent predictors of nodal metastasis. The incidence of nodal involvement for T1a tumors <2 cm was 5.4% (p < 0.004).
CONCLUSION: The incidence of potentially resectable signet ring gastric carcinoma has not changed significantly over the past decade. While presenting with predominantly high-grade histology, early T-stage disease has a high survival rate. Small T1a tumors have low rates of nodal metastasis, suggesting that an endoscopic resection could be considered in this subset.

Entities:  

Keywords:  Endoscopic mucosal resection; Endoscopic submucosal dissection; Gastrectomy; Gastric cancer; Gastric signet ring carcinoma

Mesh:

Year:  2018        PMID: 29313289     DOI: 10.1007/s11605-017-3500-4

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  8 in total

Review 1.  Tailored treatment for signet ring cell gastric cancer.

Authors:  V Mengardo; E Treppiedi; M Bencivenga; Mariagiulia Dal Cero; S Giacopuzzi
Journal:  Updates Surg       Date:  2018-06-09

2.  The Incidence-Based Mortality and Survival Trends in Patients with Gastric Signet Ring Cell Carcinoma.

Authors:  Xiangpan Li; Yuxin Chu; Qibin Song; Qinyong Hu
Journal:  J Oncol       Date:  2022-05-28       Impact factor: 4.501

Review 3.  Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges.

Authors:  Yang Li; Zhikai Zhu; Fuhai Ma; Liyan Xue; Yantao Tian
Journal:  Cancer Manag Res       Date:  2020-09-03       Impact factor: 3.989

4.  Quantifying the cell morphology and predicting biological behavior of signet ring cell carcinoma using deep learning.

Authors:  Qian Da; Shijie Deng; Jiahui Li; Hongmei Yi; Xiaodi Huang; Xiaoqun Yang; Teng Yu; Xuan Wang; Jiangshu Liu; Qi Duan; Dimitris Metaxas; Chaofu Wang
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

Review 5.  Signet ring cell cancer of stomach and gastro-esophageal junction: molecular alterations, stage-stratified treatment approaches, and future challenges.

Authors:  Naveena A N Kumar; Anmi Jose; Nawaz Usman; Keshava Rajan; Murali Munisamy; Preethi S Shetty; Mahadev Rao
Journal:  Langenbecks Arch Surg       Date:  2021-09-10       Impact factor: 2.895

6.  Epidemiology of Signet Ring Cell Adenocarcinomas.

Authors:  Matthew G K Benesch; Alexander Mathieson
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

7.  Improving survival of stage II-III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy.

Authors:  Yang Li; Zhikai Zhu; Fuhai Ma; Liyan Xue; Yantao Tian
Journal:  Cancer Med       Date:  2020-08-03       Impact factor: 4.452

8.  Positive lymph node ratio as a novel indicator of prognosis in gastric signet ring cell carcinoma: a population-based retrospective study.

Authors:  Feng Wei; Hongwei Lyu; Shuoer Wang; Yan Chu; Fengyuan Chen
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.